Nivolumab (Opdyta) 100mg/10mL | BMS India Originator | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Opdyta (India)

Opdyta is the India-market brand of nivolumab, the same originator PD-1 inhibitor that Bristol-Myers Squibb sells internationally as Opdivo. This presentation comes as a single-dose vial of 100 mg/10 mL (10 mg/mL) for intravenous infusion. Opdyta is BMS's own product for the Indian market, bringing the originator immunotherapy to Indian patients under a locally registered brand name.

What Is Nivolumab (Opdyta) Used For?

Nivolumab is approved across a wide range of cancers because it acts on the immune system rather than one tumour type. Its indications include melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, oesophageal cancer and gastric cancer. It is used alone or in combination with agents such as ipilimumab or chemotherapy, depending on the indication.

How Does Nivolumab Work?

Nivolumab is a human IgG4 monoclonal antibody that binds PD-1, a checkpoint receptor on T cells. Tumours use PD-1's ligands, PD-L1 and PD-L2, to switch off the immune response that would otherwise destroy them. By blocking PD-1, nivolumab removes this brake and restores the T cells' ability to recognise and attack cancer cells. This mechanism is what allows one medicine to be effective across many different tumour types.

Indications

The approved indications cover melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, oesophageal cancer, gastric cancer and malignant pleural mesothelioma. An oncologist experienced in immunotherapy should supervise treatment, and PD-L1 or MSI/MMR testing guides use in several indications.

Dosage

Nivolumab is administered by intravenous infusion over 30 minutes. The standard single-agent schedule is 240 mg every two weeks or 480 mg every four weeks, so a 100 mg/10 mL vial is typically combined to prepare the required dose. Combination regimens use different schedules by indication. Treatment continues until disease progression or unacceptable toxicity.

Side Effects

The most common side effects are fatigue, rash, musculoskeletal pain, diarrhoea, itching and nausea. Because the drug activates the immune system, it can cause immune-mediated reactions in the lungs, colon, liver, endocrine glands, kidneys and skin. These need prompt recognition and may require corticosteroids or treatment discontinuation. Patients should report new cough, diarrhoea, yellowing of the skin, unusual fatigue or skin changes without delay.

Storage

Opdyta is a refrigerated biologic that must be stored and handled by a healthcare facility. Vials are kept refrigerated and protected from light, and prepared by trained staff for intravenous infusion in a clinic or hospital setting.

Why Choose Opdyta Through GLT?

For overseas patients and institutions, sourcing the India-market Opdyta through GLT provides access to genuine BMS originator nivolumab, often at a cost advantage over Western list prices. GLT supports cold-chain logistics for this refrigerated biologic and ships from a Hong Kong-licensed facility with full documentation.

How to Order

To order Opdyta (nivolumab) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and cold-chain delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is Opdyta the same as Opdivo? Yes — Opdyta is Bristol-Myers Squibb's own India-market brand of the same originator nivolumab sold as Opdivo in the United States, Europe and China.

What vial strength is this? This presentation is a 100 mg/10 mL single-dose vial at 10 mg/mL.

How is nivolumab given? By intravenous infusion over 30 minutes, typically 240 mg every two weeks or 480 mg every four weeks.

Related Oncology Products

Baricent (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Incepta Pharmaceuticals Ltd. | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Incepta Pharmaceuticals Ltd. (Bangladesh) — an affordable alternative to Olumiant...

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

Barinib (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Drug International Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Drug International Limited (Bangladesh) — an affordable alternative to Olumiant...

Rizonib (Crizotinib) 250mg Capsules | DIL Bangladesh Generic Xalkori for ALK+ NSCLC | GLT

Rizonib 250 by Drug International Ltd (DIL), Tongi Gazipur — affordable crizotinib generic from Bangladesh

LuciAvat (Avatrombopag) 20mg*28 Tablets | Lucius Pharmaceuticals Laos | GLT

LuciAvat — avatrombopag 20mg (23.6mg maleate) film-coated tablets by Lucius Pharmaceuticals (Lao) Co., Ltd., Vientiane

Avabopa (Avatrombopag) 20mg*30 Tablets | Tongmeng TLPH Laos | GLT

Avabopa — avatrombopag 20mg by Tongmeng (Lao) Pharmaceutical and Food Co., Ltd. (TLPH), Lao Reg....

KangQuXin 康曲欣 (Avatrombopag) 20mg*10 Tablets | Beijing Continent Gyre | GLT

KangQuXin — avatrombopag by Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), China Mainland

Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Lucius Pharmaceuticals (Laos) generic orforglipron, 6-dose titration for weight management